Management of Osteopenia
Risk Stratification and Treatment
- The American College of Physicians recommends treating patients with osteopenia when the 10-year major osteoporotic fracture risk is ≥20% or hip fracture risk is ≥3% 1, 2, 3
- Treatment is also indicated for patients with a history of low-trauma/fragility fracture, regardless of FRAX score or BMD 1, 4
- The World Health Organization recommends calculating 10-year fracture risk using the FRAX tool to determine who needs pharmacologic intervention 1, 2, 3
Universal Recommendations for All Osteopenic Patients
- All patients with osteopenia should receive calcium supplementation of 1000-1200 mg/day and vitamin D supplementation of 600-800 IU/day 5, 6, 4, 2
- The American Academy of Family Physicians recommends a target serum vitamin D level of ≥20 ng/mL 4
- Lifestyle modifications, including weight-bearing exercise, smoking cessation, and limiting alcohol intake, are recommended for all patients with osteopenia 1, 2, 3, 5, 6
Pharmacologic Treatment for High-Risk Osteopenic Patients
- The American College of Rheumatology recommends oral bisphosphonates as first-line therapy for postmenopausal women and men ≥50 years meeting treatment thresholds 4
- Alternative therapies, such as IV bisphosphonates, raloxifene, denosumab, and teriparatide, may be considered for patients who are intolerant or have contraindications to oral bisphosphonates 5, 6, 4
Evaluation for Secondary Causes
- The Endocrine Society recommends evaluating all patients with osteopenia for secondary causes of bone loss, including vitamin D deficiency, hypogonadism, and hyperthyroidism 2, 3